Imexpharm Corporation announces the Board resolution dated April 23, 2019 as follows:

Article 1: Approving the report on business performance in Q1.2019:

-       Total revenue in Q1.2019: VND276.3 billion, achieving 19.1% plan, increasing 7.4% compared to Q1.2018;

-       Profit before tax in Q1.2019: VND45.4 billion, achieving 20.6% plan, increasing 10.5% compared to Q1.2018;

Article 2: Approving to set up Investment relations department.

Article 3: Approving the 2018 dividend payment in cash: 20%/par value

Article 4: Approving to choose of PwC VietNam Limited to audit financial statements in 2019.